announced Tuesday that the primary analysis of its Imbokodo study, which hoped to prove the efficacy of an attempted vaccine against HIV, found limited results and will be stopped.The trial, which began in 2017, consisted of testing the vaccine with 2,600 young women across several sub-Saharan African countries who were deemed at high risk of HIV transmission.
Women and girls in the region currently account for about 63 percent of new HIV transmissions, according to a press release.The Imbokodo vaccine regimen consisted of four vaccination visits annually.